PVC Benefit-Risk Assessment 2 — Questions and Answers
Question 1: Which framework uses a structured, quantitative approach to express benefit-risk balance as a single numeric value for regulatory decision-making?
- Multi-Criteria Decision Analysis (MCDA) (Correct answer)
- Benefit-Risk Action Team (BRAT)
- PrOACT-URL
- Effects Table
Correct answer: Multi-Criteria Decision Analysis (MCDA)
MCDA assigns weights to criteria and aggregates them into a single numeric score, enabling quantitative comparison of benefit-risk profiles.
Question 2: In the BRAT framework, what is the primary purpose of the 'value tree'?
- To rank adverse events by severity
- To organize and categorize key benefit and risk outcomes (Correct answer)
- To calculate the number needed to treat
- To document patient narratives
Correct answer: To organize and categorize key benefit and risk outcomes
The BRAT value tree hierarchically organizes key benefit and risk outcomes to ensure systematic and transparent benefit-risk assessment.
Question 3: A drug shows a 40% reduction in cardiovascular events but causes a 2% incidence of severe liver toxicity. Which metric best compares these outcomes on a common scale?
- Absolute risk difference
- Number needed to harm (NNH)
- Quality-adjusted life year (QALY) (Correct answer)
- Hazard ratio
Correct answer: Quality-adjusted life year (QALY)
QALYs incorporate both the quality and duration of life effects, enabling comparison of benefits and harms on a single utility-weighted scale.
Question 4: When a regulatory agency requests a 'benefit-risk communication plan' during a product review, what is its primary goal?
- To train sales representatives on product features
- To ensure patients and prescribers understand risks and benefits to make informed decisions (Correct answer)
- To satisfy post-marketing commitment timelines
- To document manufacturing quality standards
Correct answer: To ensure patients and prescribers understand risks and benefits to make informed decisions
A benefit-risk communication plan is designed to convey the benefit-risk profile clearly to patients and healthcare providers to support informed decision-making.
Question 5: Which ICH guideline specifically addresses the benefit-risk considerations in the context of clinical trial design for medicinal products?
- ICH E1
- ICH E8 (Correct answer)
- ICH E2E
- ICH Q10
Correct answer: ICH E8
ICH E8 (General Considerations for Clinical Studies) provides guidance on study design principles that incorporate benefit-risk thinking from early development.
Question 6: An effects table in benefit-risk assessment is BEST described as:
- A statistical model predicting drug response
- A structured display comparing magnitudes of key benefits and risks across alternatives (Correct answer)
- A regulatory submission checklist
- A list of contraindications
Correct answer: A structured display comparing magnitudes of key benefits and risks across alternatives
An effects table presents key benefits and risks side-by-side with their magnitudes and uncertainties to support transparent comparison.
Question 7: In pharmacovigilance benefit-risk assessment, 'uncertainty' refers primarily to:
- Gaps or limitations in the available evidence about benefits or risks (Correct answer)
- Disagreements between regulatory agencies
- Unknown manufacturing impurities
- Unclear patient demographics
Correct answer: Gaps or limitations in the available evidence about benefits or risks
Uncertainty in benefit-risk assessment reflects incomplete or imprecise evidence, and must be acknowledged and characterized to support sound decisions.
PVC Benefit-Risk Assessment 2
Which framework uses a structured, quantitative approach to express benefit-risk balance as a single numeric value for regulatory decision-making?